Nivolumab for ecurrent respiratory papillomatosis (JORRP) – pro
Juvenile onset recurrent respiratory papillomatosis (JORRP) is a human papilloma virus-mediated progressive benign neoplasm that affects children and young adults. Primary management consists of regular surgical debulking to maintain airway patency and vocal function. Like condyloma acuminata, JORRP is associated with immune dysregulation, and T cells isolated from papillomas express an anergic phenotype. The referenced report showed symptomatic improvement in 2 patients. The authors conclude: “The safety and activity of PD1 inhibitors in this population still need to be corroborated in clinical trials and should not yet be adopted into clinical practice.”
Wilcox LJ, Hull BP, Baldassari CM et al. Diagnosis and management of recurrent respiratory papillomatosis. Pediatr Infect Dis J 2014;33:12831284.
Ferris RL, Blumenschein Jr G, Fayette J et al. Nivolumab for recurrent squamouscell carcinoma of the head and neck. N Engl J Med 2016;2016:18561867.
B. C. Creelan et al, Clinical Activity of Nivolumab for Human Papilloma VirusRelated JuvenileOnset Recurrent Respiratory Papillomatosis. The Oncologist Volume24, Issue6 June 2019
Pages 829-835